Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 182

1.

Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.

Wattson DA, Sullivan RJ, Niemierko A, Merritt RM, Lawrence DP, Oh KS, Flaherty KT, Shih HA.

J Neurooncol. 2015 Apr 12. [Epub ahead of print]

PMID:
25864098
2.

When are signal transduction targeted therapies acting as immunotherapy?

Flaherty KT.

Cancer Biol Ther. 2015 Mar 25:0. [Epub ahead of print] No abstract available.

PMID:
25807058
3.

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.

Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV.

Eur J Cancer. 2015 May;51(7):833-40. doi: 10.1016/j.ejca.2015.03.004. Epub 2015 Mar 17.

PMID:
25794603
4.

MITF Modulates Therapeutic Resistance through EGFR Signaling.

Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw CN, Miao B, Frederick DT, Wargo JA, Flaherty KT, Jönsson G, Tsao H.

J Invest Dermatol. 2015 Mar 19. doi: 10.1038/jid.2015.105. [Epub ahead of print]

PMID:
25789707
5.

Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series.

Jones PS, Cahill DP, Brastianos PK, Flaherty KT, Curry WT.

Neurosurg Focus. 2015 Mar;38(3):E5. doi: 10.3171/2014.12.FOCUS14698.

PMID:
25727227
6.

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.

Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L.

J Clin Invest. 2015 Apr 1;125(4):1459-70. doi: 10.1172/JCI78954. Epub 2015 Feb 23.

PMID:
25705882
7.

Effectively targeting CRAF: rational serendipity targeting SRC?

Flaherty KT.

Pigment Cell Melanoma Res. 2015 May;28(3):242-3. doi: 10.1111/pcmr.12360. Epub 2015 Mar 4. No abstract available.

PMID:
25677495
8.

Gauging the Long-Term Benefits of Ipilimumab in Melanoma.

Ribas A, Flaherty KT.

J Clin Oncol. 2015 Feb 9. pii: JCO.2014.59.5041. [Epub ahead of print] No abstract available.

PMID:
25667273
9.

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG.

Nat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9.

PMID:
25665005
10.

Expanded access programmes: patient interests versus clinical trial integrity.

Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM.

Lancet Oncol. 2015 Jan;16(1):15-7. doi: 10.1016/S1470-2045(14)71161-1. Epub 2014 Dec 29. No abstract available.

PMID:
25638540
11.

EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma.

Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H.

Cancer Discov. 2015 Mar;5(3):274-87. doi: 10.1158/2159-8290.CD-14-0295. Epub 2014 Dec 26.

PMID:
25542448
12.

Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype.

Paraiso KH, Thakur MD, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS.

Cancer Discov. 2015 Mar;5(3):264-73. doi: 10.1158/2159-8290.CD-14-0293. Epub 2014 Dec 26.

PMID:
25542447
13.

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877.

PMID:
25538079
14.

Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.

Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W 3rd, Becker KG, Kossenkov AV, Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT.

Pigment Cell Melanoma Res. 2015 Mar;28(2):184-95. doi: 10.1111/pcmr.12330. Epub 2014 Dec 29.

15.

Universes collide: combining immunotherapy with targeted therapy for cancer.

Wargo JA, Cooper ZA, Flaherty KT.

Cancer Discov. 2014 Dec;4(12):1377-86. doi: 10.1158/2159-8290.CD-14-0477. Epub 2014 Nov 13. Review.

PMID:
25395294
16.

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.

Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ.

Mol Cancer Ther. 2014 Dec;13(12):3210-8. doi: 10.1158/1535-7163.MCT-14-0349. Epub 2014 Oct 15.

PMID:
25319388
17.

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R.

J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6.

PMID:
25287827
18.

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.

Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C.

Cancer Discov. 2014 Oct;4(10):1214-29. doi: 10.1158/2159-8290.CD-13-1007.

19.

Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD.

Pigment Cell Melanoma Res. 2015 Mar;28(2):135-47. doi: 10.1111/pcmr.12304. Epub 2014 Sep 1.

PMID:
25113308
20.

One Hippo and many masters: differential regulation of the Hippo pathway in cancer.

Romano D, Matallanas D, Frederick DT, Flaherty KT, Kolch W.

Biochem Soc Trans. 2014 Aug;42(4):816-21. doi: 10.1042/BST20140030.

PMID:
25109963
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk